Jane Street’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.9M | Buy |
181,600
+31,600
| +21% | +$4.19M | ﹤0.01% | 1625 |
|
|
2025
Q4 | $21.3M | Buy |
150,000
+89,700
| +149% | +$13M | ﹤0.01% | 1575 |
|
|
2025
Q3 | $8.46M | Buy |
60,300
+31,300
| +108% | +$4.24M | ﹤0.01% | 2633 |
|
|
2025
Q2 | $3.65M | Sell |
29,000
-23,300
| -45% | -$2.67M | ﹤0.01% | 3450 |
|
|
2025
Q1 | $5.78M | Buy |
52,300
+27,200
| +108% | +$3.45M | ﹤0.01% | 2725 |
|
|
2024
Q4 | $3.43M | Sell |
25,100
-50,700
| -67% | -$6.27M | ﹤0.01% | 3223 |
|
|
2024
Q3 | $8.73M | Buy |
75,800
+28,400
| +60% | +$3.89M | ﹤0.01% | 2070 |
|
|
2024
Q2 | $6.53M | Sell |
47,400
-27,200
| -36% | -$3.73M | ﹤0.01% | 2596 |
|
|
2024
Q1 | $10.3M | Buy |
74,600
+42,500
| +132% | +$5.8M | ﹤0.01% | 1783 |
|
|
2023
Q4 | $4.23M | Sell |
32,100
-20,700
| -39% | -$2.38M | ﹤0.01% | 3096 |
|
|
2023
Q3 | $5.94M | Buy |
52,800
+16,400
| +45% | +$1.73M | ﹤0.01% | 2375 |
|
|
2023
Q2 | $3.43M | Sell |
36,400
-13,100
| -26% | -$1.28M | ﹤0.01% | 3285 |
|
|
2023
Q1 | $5.01M | Buy |
49,500
+47,500
| +2,375% | +$4.94M | ﹤0.01% | 2460 |
|
|
2022
Q4 | $239K | Sell |
2,000
-186,800
| -99% | -$21.9M | ﹤0.01% | 7391 |
|
|
2022
Q3 | $20.1M | Buy |
188,800
+3,100
| +2% | +$315K | 0.01% | 1068 |
|
|
2022
Q2 | $18.1M | Sell |
185,700
-109,500
| -37% | -$10.1M | 0.01% | 1194 |
|
|
2022
Q1 | $27.7M | Buy |
295,200
+52,700
| +22% | +$4.47M | 0.01% | 1027 |
|
|
2021
Q4 | $20.7M | Buy |
242,500
+74,300
| +44% | +$6.83M | 0.01% | 1191 |
|
|
2021
Q3 | $16.1M | Buy |
168,200
+139,700
| +490% | +$13.2M | 0.01% | 1290 |
|
|
2021
Q2 | $2.77M | Sell |
28,500
-25,700
| -47% | -$2.46M | ﹤0.01% | 3715 |
|
|
2021
Q1 | $5.27M | Sell |
54,200
-5,200
| -9% | -$545K | ﹤0.01% | 2338 |
|
|
2020
Q4 | $5.69M | Buy |
59,400
+14,600
| +33% | +$1.41M | ﹤0.01% | 1981 |
|
|
2020
Q3 | $4.31M | Buy |
44,800
+23,800
| +113% | +$2.75M | ﹤0.01% | 2015 |
|
|
2020
Q2 | $2.56M | Buy |
21,000
+17,900
| +577% | +$1.98M | ﹤0.01% | 2722 |
|
|
2020
Q1 | $268K | Sell |
3,100
-10,600
| -77% | -$1.04M | ﹤0.01% | 4330 |
|
|
2019
Q4 | $1.47M | Buy |
13,700
+10,400
| +315% | +$1.09M | ﹤0.01% | 2284 |
|
|
2019
Q3 | $297K | Buy |
+3,300
| New | +$308K | ﹤0.01% | 4205 |
|
|
2019
Q2 | – | Sell |
-2,300
| Closed | -$203K | – | 5533 |
|
|
2019
Q1 | $203K | Sell |
2,300
-900
| -28% | -$75.2K | ﹤0.01% | 4642 |
|
|
2018
Q4 | $229K | Sell |
3,200
-1,700
| -35% | -$163K | ﹤0.01% | 4356 |
|
|
2018
Q3 | $602K | Buy |
+4,900
| New | +$556K | ﹤0.01% | 3393 |
|
|
2016
Q3 | – | Sell |
-32,100
| Closed | -$1.46M | – | 4345 |
|
|
2016
Q2 | $1.46M | Buy |
+32,100
| New | +$1.48M | 0.01% | 1579 |
|
Other funds holding NBIX
VPM
VCM
Jane Street's NBIX Position: Q1 2026 in Review
Jane Street increased its Neurocrine Biosciences (NBIX) stake by 19% in Q1 2026, buying an estimated $134K and bringing the position to 6,207 shares worth $818K. The position accounts for ﹤0.01% of the portfolio, ranked #6933.
Jane Street first reported a position in NBIX in Q2 2013 and has held it in 44 quarters since. The position peaked at $34.8M in Q1 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Jane Street held 6,207 shares of Neurocrine Biosciences worth $818K as of Q1 2026.
- Jane Street bought 1,010 Neurocrine Biosciences shares in Q1 2026, an estimated $134K.
- Neurocrine Biosciences made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6933 holding.
- Jane Street first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 44 quarters since.
- Jane Street's Neurocrine Biosciences position peaked at $34.8M in Q1 2024.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.